Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC.

(IMMU)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Immunomedics : Wall Street posts solid gains after surge in corporate deals

share with twitter share with LinkedIn share with facebook
09/14/2020 | 10:45am EDT

Wall Street ended solidly higher Monday following a burst of big corporate deals. The S&P 500 rose 1.3%, erasing much of its loss from last week. Technology companies led the gains once again. Nvidia jumped after announcing plans to buy fellow chipmaker Arm Holdings, and Oracle climbed after the business software maker beat out Microsoft to become the tech partner of TikTok, the popular video-sharing app based in China. Immunomedics nearly doubled after the cancer drug specialist agreed to be acquired by Gilead Sciences. European markets were mixed and Asian markets closed broadly higher. Treasury yields held steady.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story appears below.

Wall Street kicked off the week with a broad rally Monday, clawing back much of the stock market's losses from last week.

The S&P 500 was up 1.4%, led by gains in technology, health care and financial stocks. Small company stocks were among the biggest gainers. The rally reversed a big slice of the index's 2.5% slide last week, when the S&P 500 posted its biggest weekly decline since June. Treasury yields were mostly higher.

The market's strong start to the week is a reversal after a mostly downward shift in the market this month led by a sell-off in high-flying tech stocks that many analysts said was long overdue.

“We’ve been due for a little bit of a pullback, and we’ve experienced that so far in September,” said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management. “We still have a positive outlook into the end of the year, but we believe market chop will be the norm.”

The Dow Jones Industrial Average was up 331 points, or 1.2%, to 27,999 as of 3:39 p.m. Eastern time. The Nasdaq, which includes many tech stocks, rose 2%. Small company stocks were notching solid gains, sending the Russell 2000 index 2.3% higher.

Several big corporate deals helped put investors in a buying mood Monday. Nvidia jumped 5.8% after announcing plans to buy fellow chipmaker Arm Holdings in a deal worth up to $40 billion. Oracle climbed 4.8% after the business software maker beat out Microsoft to become the “trusted technology provider” of TikTok, the popular video-sharing app based in China. And the stock of Immunomedics nearly doubled after the cancer drug specialist agreed to be acquired by Gilead Sciences in a $21 billion deal. Gilead shares rose 2.5%.

AstraZeneca added 0.5% following news over the weekend that clinical trials for the pharmaceutical company's coronavirus vaccine will resume after being paused due to a reported side-effect in a patient in the U.K. The vaccine is seen as one of the strongest contenders among the dozens of coronavirus vaccines being tested.

Wall Street has been riding a surge in volatility the past couple of weeks as investors turned cautious following a five-month rally for stocks fueled largely by a run-up in big tech companies.

The pandemic accelerated the use of online services by businesses and individuals, driving shares of Apple, Amazon, Microsoft, Zoom Video and other tech companies sharply higher through the summer. But concerns that the high-flying tech stocks had soared too high have put investors in a selling mood in September. The S&P 500 is down 3.3% so far this month, while the Nasdaq has pulled back 6.1%.

“We know that momentum is going to slow a little bit, that’s expected,” said Esty Dwek, head of global market strategy at Natixis Investment Managers. “It wasn’t supposed to be, or it was never going to be a straight line without any bumps in the road.”

Despite its September stumble, stocks retain much of their gains since setting record highs less than two weeks ago. The S&P 500 is up 4.7% for the year. The Nasdaq is up 23.2%. Even so, analysts expect more volatility for stocks in the months ahead as the market navigates uncertainty over the outcome of the election, pessimism that Democrats and Republicans in Washington will be able to find a deal to send more aid to unemployed workers and an economy still struggling amid the pandemic.

One big factor that remains in the stock market’s favor is the Federal Reserve, which continues to pump aid into the economy. It has slashed short-term interest rates to record lows and bought up all kinds of bonds to support markets. It also said recently it will keep delivering stimulus even if inflation rises above its target level, as long as inflation had been well under it before then.

Investors will be focused this week on the central bank's latest interest rate and economic policy update on Wednesday, following a two-day meeting of policymakers. After the July meeting, the Fed kept its key interest rate unchanged at a record low near zero. Fed policymakers also pledged to keep rates low until they are confident that the economy has weathered the pandemic-induced recession.

Low rates often act like steroids for Wall Street, encouraging investors to pay higher prices for stocks relative to corporate profits, which can benefit high-growth stocks in particular.

Traders also will have their eye on a batch of new data due out this week on U.S. home construction, retail sales and consumer sentiment. Housing has been a highlight of the economic recovery as ultra-low interest rates have helped drive home sales and spurred builders to ramp up construction. Homebuilder stocks have been climbing even during the market pullback much of this month.

The yield on the 10-year Treasury held steady at 0.67%.

European markets ended mixed, while Asian markets closed broadly higher.

Yuri Kageyama is on Twitter https://twitter.com/yurikageyama

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News


Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -3.18% 58.72 Delayed Quote.-10.59%
IMMUNOMEDICS, INC. 0.05% 87.86 End-of-day quote.315.22%
share with twitter share with LinkedIn share with facebook
All news about IMMUNOMEDICS, INC.
10/26GILEAD SCIENCES : Completes Acquisition of Immunomedics, Inc.
AQ
10/23IMMUNOMEDICS INC : Completion of Acquisition or Disposition of Assets, Notice of..
AQ
10/15GILEAD SCIENCES : Announces Expiration of Hart-Scott-Rodino Waiting Period for I..
AQ
10/12IMMUNOMEDICS : Announces FDA Orphan Drug Designation of Trodelvyᵀᴹ f..
PU
10/12IMMUNOMEDICS : Announces FDA Orphan Drug Designation of Trodelvy™ for Adul..
AQ
10/12Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adu..
GL
09/25WEISSLAW LLP : Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing Investi..
PR
09/25WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Inve..
PR
09/24GILEAD SCIENCES : Prices $7.25 Billion of Senior Unsecured Notes
AQ
09/21IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 146 M - -
Net income 2020 -235 M - -
Net cash 2020 480 M - -
P/E ratio 2020 -84,5x
Yield 2020 -
Capitalization 20 324 M 20 324 M -
EV / Sales 2020 136x
EV / Sales 2021 58,1x
Nbr of Employees -
Free-Float 97,7%
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Behzad Aghazadeh Executive Chairman
Usama Malik Chief Financial & Business Officer
Loretta M. Itri Chief Medical Officer
Peter Barton Hutt Independent Director
Scott A. Canute Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.315.22%20 324
LONZA GROUP AG63.59%47 362
SEAGEN INC.70.51%34 263
IQVIA HOLDINGS INC.1.15%30 511
CELLTRION, INC.32.04%28 321
MODERNA, INC.240.08%27 885